The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy
作者
Ma, HH;Zhang, TH;Shen, HC;Cao, HX;Du, JJ
作者单位
[Ma, Honghai] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan 250021, Peoples R China.;-;[Zhang, Tiehong; Shen, Hongchang; Cao, Hongxin; Du, Jiajun] Shandong Univ, Prov Hosp, Inst Oncol, Jinan 250021, Peoples R China.
摘要
Aim(s) Insulin-like growth factor-1 receptor (IGF-1R) targeted therapies have become one of the intriguing areas in anticancer drug development during the last decade. As one of these therapies, anti-IGF-1R monoclonal antibodies (mAbs) are also advancing further in development. Our purpose was to conduct a systematic review of the adverse events (AEs) caused by anti-IGF-1R monoclonal antibodies in cancer therapy. Methods We searched the termIGF-1R monoclonal antibody' in the Pubmed database and found 389 related articles. After elaborate selection, 15 clinical studies that satisfied our criteria were then adopted for further analysis. We extracted all the useful information about the AEs of mAbs from the enrolled studies. Every kind of reported AE as well as corresponding incidences were summed up and calculated. We compared AE incidence differences in two age groups, and analyzed toxicities of mAbs used as a single agent or combined with chemotherapies. Finally, the differences of AE profiles between individual mAbs were also valued. Results AEs were more severe in the lower age group and 13 of 19 AE incidences in the single-agent group were significantly lower than in the combination group (P < 0.05). R1507 seemed to show a worse AE profile than cixutumumab and figitumumab. Conclusions When anti-IGF-1R mAbs are used for cancer therapy, it is essential to choose the proper drug and combined chemotherapies to reduce AE occurrences. Also, administration of these mAbs to younger patients should be more carefully supervised. Furthermore, some more frequently observed AEs for specific mAb should be paid adequate attention.
关键词
GROWTH-FACTOR-I; CELL LUNG-CANCER; ADVANCED SOLID TUMORS; INHIBITOR FIGITUMUMAB CP-751,871; FACTOR RECEPTOR INHIBITORS; PHASE-II; EWING SARCOMA; COMBINATION; CIXUTUMUMAB; ONCOLOGY
基本信息
